 |
 |
|
|
Resources for Food and Drug Administration (FDA)Resources > FDA > ArticlesSub-Categories: Listings 261 - 270 of 2154:
Critics question FDA, U.S. Customs handling of Ranbaxy case
For two and a half years, the Food and Drug Administration collected evidence that Ranbaxy Laboratories, India's largest generic drugmaker, may have l...
Critics Top Shortlist for FDA Head
A doctor who once denounced Pfizer Inc. for holding a marketing event in a pool hall is leading President-elect Barack Obama's team formally assessing...
CryoLife gets FDA update on heart valve label
CryoLife Inc., which processes human tissue for transplant procedures and makes the stitch replacement BioGlue, said Tuesday the Food and Drug Adminis...
CSL Behring’s agioedema drug gets FDA's Approval
Berinert, a treatment developed by CSL Behring ha sbeen granted marketing approval by the Food and Drug Administration for acute abdominal or facial ...
CSL Gets FDA Approval for Its RiaSTAP Fibrinogen Product
CSL Behring's human fibrinogen concentrate RiaSTAP, sold for years in Europe as Haemocomplettan P, will be welcomed for management of bleeding problem...
CSPI Calls On FDA To Ban Eight Food Dyes
The Center for Science in the Public Interest (CSPI) yesterday called on the U.S. FDA to ban eight food dyes, used in products including General Mills...
CSPI Urges FDA to Facilitate Adverse Reaction Reporting for Dietary Supplements
The Food and Drug Administration (FDA) is under pressure from the dietary supplement industry to weakly implement a law intended to prevent a repeat o...
CT scan alert for pacemakers
The Food and Drug Administration is warning doctors and patients that electronic devices such as pacemakers, cardiac defibrillators and insulin pumps ...
CV angina drug action delayed by FDA
Cardiovascular drug maker CV Therapeutics Inc. of Palo Alto said the Food and Drug Administration pushed its review of the angina drug Ranexa beyond ...
CV Therapeutics: FDA to Review Ranexa
Biopharmaceutical company CV Therapeutics Inc. said Monday federal regulators will review its chest pain drug Ranexa as an initial treatment for angin... |
|
RSS Feeds|
Privacy Policy | Terms & Conditions | Support | Directory Links | Contact Us | Site Map | Home Copyright © 2007-2010 ComplianceHome.com. A SUPREMUS GROUP venture. All rights reserved. |
 |
 |